Targeted synthetic and biosimilar disease modifying antirheumatic drugs in pregnancy: Patterns of use among females with rheumatic diseases and outcomes

Our proposed research project aims to answer the overall question: how do new arthritis medications taken during pregnancy affect mothers and their children? Many types of arthritis strike in females during their childbearing years. Even though we now know more about the effects of arthritis drugs when taken during pregnancy, the picture is not yet complete. Most of what we know is on impacts on babies with lesser information about impacts into childhood and on mothers. We also do not know how very much about how newer drugs, such as biosimilars and targeted therapies, are being used during pregnancy and their impacts. To solve this problem, we will use “big healthcare data” in British Columbia (BC) which contains key information on prescription drugs and a pregnancy registry. We will apply state-of-the art statistical methods to these data to study use of these medications during pregnancy and the health of mothers and their children.

Faculty Supervisor:

Mary De Vera

Student:

Partner:

Arthritis Research Canada

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Pharmaceuticals

University:

The University of British Columbia

Program: